Ruminant Trans Fats and the Risk of Cardiovascular Disease in Women (TRANSW)

March 4, 2013 updated by: Benoit Lamarche, Laval University

While the deleterious effects of trans fat from industrial sources (iTFA) on cardiovascular health are well established, the impact of TFA from ruminants (rTFA) on cardiovascular risk factors has not been as well characterized. We have previously shown in men that a very high dietary intakes of rTFA (>3.5% of energy) leads to unfavourable changes in lipid cardiovascular risk factors that are similar to those seen with iTFA. However, our data also indicated that achievable intakes of rTFA that remain well above the current human consumption (1.5% of energy intake) had neutral effects on plasma lipids and other cardiovascular disease (CVD) risk factors in men. Other studies have also suggested that the LDL and HDL response to very high dietary intakes of rTFA (>5% of energy) in women may be different than in men.

The general objective of the study is to investigate for the first time in a double-blind randomized controlled study the impact of high but yet achievable intake of ruminant trans fatty acids on plasma LDL-Cholesterol and other risk factors for CVD in healthy women.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Ruminant trans fatty acids (rTFA) will come from an experimental butter formulated from dairy fat obtained after having modified the regimen of lactating cows. All diets will be identical in terms of menus, calories and macronutrient composition with the exception of TFA levels. All foods will be provided to study participants. Based on a 2500 kcal/day regimen, an intake of 4.1g of rTFA will represent 37 kcal/day (1.5% of energy intake) while the intake of 0.7 g of rTFA in the control diet will represent 6 calories (0.3% of energy). The 2 experimental diets will be formulated so that the percentage of daily calories from fat (33%), carbohydrates (52%) and proteins (15%) will meet the dietary recommendations of the American Heart Association and the NCEP for primary prevention of CVD.

Study Type

Interventional

Enrollment (Actual)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Quebec, Canada, G1V 0A6
        • Institute of Nutraceutical and Functional Foods (INAF), Laval University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Healthy women using or not contraceptive agents or hormone supplementation
  • For pre-menopausal women: regular menstrual cycle for the last 3 months (25- 35 days)
  • LDL-Cholesterol concentration between 2.5 and 4.0 mmol/L
  • Stable body weight (+/- 2 kg) for 6 months before the beginning of the study
  • Smoking or not

Exclusion Criteria:

  • Previous history of cardiovascular disease, type 2 diabetes and monogenic dyslipidemia
  • Subjects taking medications for hyperlipidemia or hypertension
  • Endocrine disorders
  • Body mass index > 35 kg/m2
  • Food allergies
  • Women with extreme nutritional habits such as vegetarism or alcohol consumption > 2 drinks/day
  • Elite athletes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High dairy trans fat
a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal)

Consumption of the 2 experimental diets

  1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);
  2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal).
Active Comparator: Low dairy trans fat diet
a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)

Consumption of the 2 experimental diets

  1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);
  2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Plasma LDL-Cholesterol concentrations
Time Frame: At the beginning of the study and the end of the 2 for-week diets
At the beginning of the study and the end of the 2 for-week diets

Secondary Outcome Measures

Outcome Measure
Time Frame
Blood lipids and apolipoproteins (Total cholesterol, HDL-Cholesterol, Triglycerides, Apo A1, Apo B)
Time Frame: At the beginning of the study and the end of the 2 for-week diets
At the beginning of the study and the end of the 2 for-week diets
CRP
Time Frame: At the beginning of the study and the end of the 2 for-week diets
At the beginning of the study and the end of the 2 for-week diets
Blood pressure
Time Frame: At the beginning of the study and the end of the 2 for-week diets
At the beginning of the study and the end of the 2 for-week diets
Anthropometric measures (waist and hip circumferences)
Time Frame: At the beginning of the study and the end of the 2 for-week diets
At the beginning of the study and the end of the 2 for-week diets

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Benoît Lamarche, PhD, Institute of Nutraceutical and Functional Foods (INAF), Laval University
  • Study Director: Patrick Couture, MD, FRCP (C, PhD), Faculty of Medicine, Laval University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2009

Primary Completion (Actual)

December 1, 2010

Study Completion (Actual)

September 1, 2011

Study Registration Dates

First Submitted

June 29, 2009

First Submitted That Met QC Criteria

June 29, 2009

First Posted (Estimate)

June 30, 2009

Study Record Updates

Last Update Posted (Estimate)

March 5, 2013

Last Update Submitted That Met QC Criteria

March 4, 2013

Last Verified

March 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • INAF-2009-084

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.